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Abstract
Occupational therapists need a means to efficiently and accurately screen a
client’s medication management capacity, especially for clients post-stroke. Most
therapists are not aware of, nor do they utilize specific assessments for medication
management capacity, partly due to lack of thorough assessments. The purpose of this
study was to compare the scores of the ManageMed Screen (MMS), the Screening for
Self-Medication Safety Post Stroke (S5), and the Montreal Assessment of Cognition
(MoCA) on a population of rehabilitation clients post-stroke to evaluate consistency of
scores and determine their usefulness in clinical practice. All screens were designed for
use in occupational therapy; the MMS was validated for the general adult population, the
S5 for clients post-stroke, and the MoCA is a cognitive screen used with adult clients
with a variety of diagnoses including stroke. The MoCA was used to explore the potential
relationship between cognition and medication management capacity. Study participants
included five clients post-stroke and three occupational therapists. Clients were screened
by the occupational therapists with the MMS, S5, and MoCA, and clinicians also
participated in a focus group to assess their perceived usefulness of the screens. Results
demonstrated that the MMS was consistent with the S5 in identifying the clients who
performed the poorest. The MoCA has no consistent relationship with either the MMS or
S5. Additionally, through a focus group, clinicians deemed both the MMS and S5 as
useful, but felt the MMS was a more useful screen for their clinical practice in regards to
efficient and practical use with clients post-stroke in a rehabilitation setting.
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Introduction
This capstone paper presents combined findings from quantitative and qualitative
studies conducted to determine the usefulness of two fairly new medication management
screens in occupational therapy practice. The first few sections of this paper provide a
background to the topic, a literature review highlighting key factors of cognition, stroke
medication and issues pertinent to medication management capacity post-stroke.
Medication management capacity screens and a statement of the problem for this
capstone follows. The research study is then presented in the methodology section
outlining the design, participants, instrumentation and procedure. Results and discussion
ensue with a conclusion on the usefulness (e.g. accuracy, efficiency and practicality) of
the medication management capacity screens. This paper ends with the implications for
occupational therapy practice and suggestions for future research.
Background
The capacity for medication management is of eminent concern for health
professionals as there is an increase in chronic disease and medication dependency
among older adults (Orwig, Brandt, & Gruber-Baldini, 2006; Robnett, Dionne, Jacques,
Lachance, & Mailhot, 2007). Poor medication management is related to an increased
number of medication errors, hospital admissions and higher mortality rates in the older
adult and those with chronic health issues, such as stroke (Elliott & Marriott, 2009; Hayes,
Larimer, Adami, & Kaye, 2009). Medication management capacity is the result of intact
higher level cognitive skills which enable a person to be independent and safe with this
task. In our practice, occupational therapists are charged with assessing medication
management capacity as it can impact independence and safety with daily functioning.
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Statement of the Problem
Best practice in occupational therapy would indicate the use of comprehensive
and psychometrically strong tools for client assessment when available (AOTA, 2008). In
current practice, specifically in the rehabilitation setting, one often will find clinicians
using clinical inference from observation of activities of daily living or ‘home grown’
screens or questionnaires to assess medication management capacity. Health
professionals, such as occupational therapists, are not good at predicting a client’s ability
with medication management based on observation; functional ability of this task is not
always detected in routine assessments or observations (Elliott & Marriott, 2009). Wales,
Clemson, Lannin & Cameron (2012) found that occupational therapists often do not use
standardized assessment in practice due to their readiness, skill, time commitments,
“motivation, self-confidence, lack of support from management, personal values and
beliefs and lack of knowledge” or awareness of the availability of assessments (p. 2).
Clinical judgment of performance of functional tasks, such as medication management,
when completed in an unstructured and non-standardized manner, leads to decreased
legitimacy and limited contributions to evidence-based outcomes in occupational therapy
(Doucet & Gutman, 2013; Elliott & Marriott, 2009). Using standardized and normed
instruments in clinical practice can assist with efficiency, documentation of changes in
status, and improves overall effectiveness of occupational therapy practice (Doucet,
2013). Thus the approach to medication management capacity screening traditionally has
not been standardized in occupational therapy, most likely due to lack of awareness of
available screens and/or screens are not available for a specific population, such as clients
post-stroke.
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There are about a dozen screens in the open market labeled as medication
management capacity screens (Appendix A); however upon further review of these
screens we find many are not appropriate for use with clients post-stroke as they lack
research on this population and key components within the screen specifically to assess
cognitive and physical skills of clients post-stroke. The literature also indicates that
assessing cognition alone does not equate to an accurate screen for medication
management capacity, and for the stroke population physical performance must also be
assessed (Donovan et al. 2008). Thus some of the screens only address cognition.
Furthermore, many of these screens are profession specific (not occupational therapy),
diagnosis specific (not stroke), or do not measure medication capacity, but rather
adherence patterns.
When reviewing the literature on medication management capacity, the reader
will find a plethora of research articles which discuss medication compliance or
adherence. What is of concern for this capstone is the capacity to follow a medication
routine based on a client’s cognitive and physical performance (not their choice to adhere
to their prescribed medication routine). For a client post-stroke, the ability to manage
medications can be impacted by changes in communication skills, physical abilities,
cognition, behavior, sensation and visual-perception (Kaizer, Kim, Van, & KornerBitensky, 2010). Up to 65% of stroke survivors demonstrate changes in cognitive
function including attention deficits, memory deficits, and spatial neglect, all of which
can impact functional recovery and safety with medication management (Donovan et al.,
2008; Wolf, 2006). To ensure clients post-stroke have the physical and cognitive skills
for safe medication management, screens that are valid and reliable for this population to
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assess these skills are needed. For this capstone, the focus will be specifically on clients
post-stroke as this population typically will present with cognitive and physical
performance deficits that can impact their capacity for safe and independent medication
management.
Consensus from the literature also indicates that there is currently no gold
standard assessment (e.g. best performing test) to measure medication management
capacity in typical adults, let alone for those with specific diagnoses such as stroke
(Elliott & Marriott, 2009; Donovan et al., 2008). There are about a dozen medication
management screens that have been used over a few decades in various professions, but
all have short-comings for use in occupational therapy and/or for clients post-stroke. As
of early 2007, no published instrument with sufficient evidence of reliability and validity
has been published to enable its recommendation for routine use in clinical practice
(Elliott & Marriott, 2009).
Since 2007, two medication management screens have been developed and were
found to be appropriate for use in occupational therapy: the ManageMed Screen (MMS)
and the Screening for Self-Medication Safety Post Stroke (S5) (Robnett et al., 2007;
Kaizer et al., 2010). The MMS and S5 were developed to meet the need for occupational
therapists by addressing cognitive and physical performance skills required for
medication management. The MMS was specifically developed by occupational
therapists for assessing medication management with the general adult population; it is
able to differentiate between adults who need assistance and those who are independent
with this task (Robnett et al., 2007). The MMS is standardized and has undergone
validation studies as well (Robnett et al., 2007). The S5 was developed for occupational
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therapists to assess medication management capacity for clients post-stroke (Kaizer et al.,
2010). The S5 has undergone only one pilot testing by its authors for use with adult
clients post-stroke; thus the S5 has limited data to support its reliability and validity.
These screens continue to need clinical research to support their use in specific client
populations, such as stroke. In a rehabilitation setting for clients post-post, clinicians need
a practical screen(s) that will accurately and efficiently assess each client’s cognitive and
physical skills required to manage their medications. Clinicians generally are not using
standardized assessments nor is there a gold standard for medication management
capacity screening. This study will review two screens to address this need in clinical
practice.
Research Aim
The purpose of this capstone was to determine which screen(s) is the most useful
for occupational therapists based on quantitative and qualitative data. Assessing if the
MMS and S5 are consistent in identifying clients who have poor medication management
capacity skills can provide occupational therapists with more screening tools to use in
practice, as there is a lack of standardized assessments for clients post-stroke to assess
medication management capacity (StrokEngine, 2013a). Furthermore, qualitative
information about these screens can give insight into their usefulness (defined for this
capstone as accuracy, efficiency, and practicality) in clinical practice. Therefore, this
capstone pilot study’s aim is to answer the following questions:
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Research Questions
1. How consistent are the ManageMed Screen (MMS) and the Screening for SelfMedication Safety Post-Stroke Scale (S5) scores for assessing capacity in medication
management?
2. How consistent are the ManageMed Screen (MMS) and the Screening for SelfMedication Safety Post Stroke Scale (S5) scores compared to the Montreal Cognitive
Assessment (MoCA) for assessing cognition as an indicator for capacity in medication
management?
3. Which of the medication management screening tools (or aspects of each screen) offer
the most clinically relevant information to help inform decision making for treatment and
discharge planning for medication management capacity for occupational therapy
practitioners?
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Literature Review
Introduction
This review provides a synopsis of literature about medication management
capacity versus medication adherence, cognitive and physical performance deficits that
are essential to consider when reviewing currently available medication management
screens, and performance factors impacted by medications which clients post-stroke may
be taking. Additionally, a summary of medication management screens used across
different professions will be presented to highlight the need to assess these particular
medication management screens for continued use in occupational therapy. The literature
review will conclude with a rationale for the need for this capstone study in which
specific medication management screens are compared for use with clients post-stroke
and their impact on clinical practice in occupational therapy is investigated.
Medication Adherence versus Medication Management Capacity
In the literature, the terms medication capacity and medication adherence are
often used interchangeably, when in fact theses terms are fundamentally different.
Medication adherence speaks to patterns or reasons individuals are not taking
medications and not to the capacity to do so (Orwig, Brandt & Gruber-Baldini, 2006).
Adhering to medications does not equate capacity to manage medications; for example, a
client may be able to administer their medications daily, but perhaps are not able to
follow the proper dose or instructions. Non-adherence includes client reasons for not
taking medications routinely, which may be due to difficult medication schedules, lack of
education on use of the medicine, lack of counseling, possible side effects, poor lifestyle
adaptation, social vulnerability, polypharmacy, physical or cognitive impairments,
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decreased communication skills, and financial considerations (Hayes et al., 2009; Robnett
et al., 2007; Stilley, Bender, Dunbar-Jacob, Sereika, & Ryan, 2010).
In comparison, medication management capacity involves the skills and abilities
to manage a medication routine; therefore, encompassing the cognitive and physical
abilities needed to track, plan, and physically manipulate medications (Kaizer et al.,
2010; Robnett et al., 2007). Medication management capacity encompasses a complex set
of tasks involving intrinsic and extrinsic performance factors that can impact client safety
(Stilley, et al., 2010). Intrinsic factors include the skills of attention, memory, perception,
executive function, problem solving, reading, and insight; these skills enable
understanding, planning, tracking, and taking medications as prescribed (AOTA, 2008;
Neupert, Patterson, Davis, & Allaire, 2011; Robnett et al., 2007). Extrinsic factors
related to managing medications include contexts such as the physical environment
[home setup, tools or device use], client’s age, social support, cultural influences or
beliefs, factors such as socioeconomic status, and belief or non-belief in medical
treatment (AOTA, 2008; Neupert et al., 2011). All of these factors can also influence if or
how a client will be able to follow through with a medication routine.
For example, the Medication Management Instrument for Deficiencies in the
Elderly (MedMaIDE) is a screen designed to assess compliance or adherence of
medications in the elderly – specifically knowledge of medications, how to take
medications, and how to obtain medication (Orwig et al., 2006). This assessment does not
assess cognitive and physical skills needed to safely and independently manage
medications. A test such as the MMS contains tasks which assess short-term memory,
safety, planning a task, and physical manipulation of items needed to carry out a
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medication routine (Robnett et al., 2007). There are a limited number of studies that
purely research medication management capacity, but by understanding the distinction of
adherence versus capacity, one will understand how some screens labeled to assess
capacity are actually assessing adherence, and therefore not beneficial for use in
occupational therapy practice when the intent is to assess capacity. Some studies that
discuss adherence were included in the literature review as they do reflect the importance
of addressing cognition in relation to medication management capacity which can be
impacted by stroke.
Cognition, Stroke and Medication Management
The literature suggests that a person’s cognition impacts his/her ability to safely
and effectively manage daily living tasks, such as medication management. Assessment
of cognitive performance of a client post-stroke is needed in occupational therapy to
determine the client’s baseline and identify possible deficits from his/her stroke for
intervention planning and discharge recommendations. Poor cognitive skills have been
found to impact safety and independence with medication management capabilities in
research studies time and time again.
Hayes et al. (2009) investigated the cognitive abilities of healthy independently
living elders to follow a medication regimen in a five week long study. Thirty-eight
participants were divided into two groups (high cognitive function [HCF] and low
cognitive function [LCF]) based on outcomes of cognitive testing using the Alzheimer’s
Disease Assessment Scale (Graham, Cully, Snow, Massman, & Doody, 2004) and the
Mini Mental State Exam (Folstein, Folstein, & McHugh, 1975). Researchers added a
daily vitamin C regime to the participants’ current medication routine. The participant’s
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ability to manage medications was measured using a seven-day electronic pill bottle that
tracked the time and frequency the pill bottle was opened. Additionally, a self-assessment
questionnaire was provided for participants to complete at the end of the study. The
authors found that the participants in the LCF group had poorer adherence (27.8%) to
their medication routine than their counterparts in the HCF group (75%) (with 80%
adherence considered good). This finding could be attributed to the participant’s ability to
understand, plan and track their medication routines given their degree of cognitive
impairment. While this study was concerned with adherence patterns, its does signify that
cognitive function is an important aspect to assess in medication management capacity.
There is a general consensus in the literature regarding cognitive decline and
stroke; “cognitive impairment is higher among stroke survivors than among age-matched
stroke-free adults” (Wang, Capistrant, Ehntholt, & Glymour, 2012, p. 1). The study by
Wang et al. analyzed 10 years worth of data from the Health and Retirement Study (HRS)
(the HRS is a large, national cohort study of adults 50 years and older, initially without
stroke) to examine the long-term pre-stroke and post-stroke memory changes among
stroke survivors. Performance-based and informant-based assessments of immediate and
delayed memory recall and incidence of stroke were of interest for this study (Wang et
al.). The authors looked at the annual rate of memory change through linear and
curvilinear trends and concluded that stroke survivors’ cognitive function significantly
declined with each passing year. Memory decline among those surviving stroke was 42%
faster than those with no recorded stroke. Evidence of cognitive impairments can be
related to ischemic injury, silent strokes, and other stroke symptoms (Wang et al., 2012).
While this study did not examine medication management capacity, it highlights the
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importance of screening cognition (including memory and other aspects of cognitive
functioning required for medication management) post-stroke to ensure safety and ability
in all pertinent activities of daily living.
In a study of predictors for health risk management among stroke survivors,
researchers found that cognitive losses can contribute to stroke as well as being an
outcome of stroke (Ireland, Arthur, Gunn, & Oczkowski, 2011). Cognitive skill loss is
associated with older age, is a precursor to stroke (e.g. transient ischemic attacks), and/or
the incidence of previous stroke increases the risk of having subsequent strokes due to
clients’ potential inability to effectively manage their health. Study participants poststroke who were found to have executive function decline and/or visual perceptual
changes led to a higher risk for poor outcomes, such as not having the capacity to follow
their plan of care (e.g. medication routine, follow up appointments, etc) (Ireland et al.,
2011). This study highlights the need to have a medication management capacity screen
that is designed for clients post-stroke to accurately and efficiently assess cognitive skills.
In 2008, Donovan et al., sought to conceptualize cognition for clients post-stroke
to enable more focused research in this area. Current clinical trials for stroke recovery
often focus solely on physical recovery, thus the influence of changes in cognition poststroke has not been well studied (Donovan et al., 2008). Through an extensive literature
review, the authors of this study proposed 10 domains of functional cognition related to
stroke as a means to study recovery centered on vascular distribution, neuroanatomic
damage, and cognitive impairment following a stroke. The domains include: language
abilities, reading and writing, numeric/calculation, limb praxis, visuospatial function,
social use of language, emotional function, attention, executive function, memory
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(Donovan et al., 2008). For medication management capacity, all these cognitive skills
are used to plan, track and manipulate medications (Kaizer et al., 2010; Robnett et al.,
2007). When reviewing a potential medication management capacity screen, the domains
defined by Donovan et al., (2008) should be considered key components to assess in
relation to medication management capacity. Given the complexity of the skills
demanded by this health management task, a comprehensive screen incorporating
performance-based assessments of cognitive and physical skills is needed rather than
purely a cognitive screen.
Cognitive and Physical Assessment Post-Stroke
Cognition.
Cognitive function post-stroke is often assessed immediately upon admission to a
hospital or rehabilitation center, as the presence of cognitive impairment can impact the
potential for successful rehabilitation (Aggrawal & Kean, 2010). Occupational therapists
have access to an assortment of cognitive assessments including standardized
assessments such as the Cognistat (Kiernan, Mueller, Langston, & Van Dyke, 1987),
Mini Mental State Exam (MMSE) (Folstein, Folstein & McHugh, 1975) or the Montreal
Assessment of Cognition (MoCA) (Nasreddine et al., 2005) as well as non-standardized
assessments such as ones devised by clinicians or setting specific developed tests or
questionnaires. These assessments alone are not sufficient enough to assess medication
management capacity in clients post-stroke, but should be used to help identify areas of
cognition (e.g. memory, sequencing) that are negatively impacting safety with medication
management.
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The Cognistat is often cited as the gold standard of cognitive assessments as it has
withstood years of validity and reliability research. This tool assesses language,
constructions, memory, calculations, and reasoning (Kiernan, et al., 1987). The Cognistat
has well defined validity and reliability across the lifespan and diagnoses; however, its
administration is often lengthy and it is suggested the screen be scored by
neuropsychologists, not always readily available for use by the occupational therapy
practitioner (Friedman, 2012). The MMSE was designed to be a briefer tool to assess
language, construction, and memory skills for the detection of cognitive impairment and
differentiation of dementias (Aggrawal & Kean, 2010). Through further years of research
the MMSE was found to have poor sensitivity for the detection of mild cognitive
impairment (Aggrawal & Kean, 2010). To that end, the MoCA was developed as a brief
screening tool to detect mild cognitive impairment and has been studied for use with
clients post-stroke (Nasreddine et al., 2005). The MoCA examines attention and
concentration, executive functions, memory, language, visuoconstructional skills,
conceptual thinking, calculations, and orientation (Nasreddine, 2013). The MoCA is often
used in clinical practice as it is brief, assesses an array of cognitive skills and provides a
cutoff score for poor versus intact performance (Nasreddine, 2013).
In a study comparing the MMSE and MoCA for clinical use in a rehabilitation
setting, Aggrawal & Kean (2010) found the MMSE did not perform as well for the
detection of mild cognitive impairment. Even though the MoCA can take slightly longer
to administer, the general consensus of occupational therapists is that the MoCA is a
more comprehensive test, has adequate psychometrics, has multiple versions and
language options, and has normative values that are easy to understand (Aggrawal &
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Kean). In a study by Pendlebury, Cuthbertson, Welch, Mehta, & Rothwell (2010),
researchers found that in a population of clients post transient ischemia attack (TIA), the
MoCA detected more cognitive deficits than the MMSE. For the purpose of this capstone
pilot study, the MoCA was therefore used to explore the relationship between cognition
and medication management capacity for clients post-stroke.
Physical assessment.
Physical assessment of motor-performance skills is also completed in hospitals or
rehabilitation facilities for clients post-stroke (AOTA, 2008). For independence in daily
occupations, clients need adequate motor-performance skills often compromised by
stroke. A variety of deficits can occur post-stroke; when classifying a stroke by cerebral
hemisphere lesion alone, a stroke in the right hemisphere can affect sensory and motor
skills of the left side of the body, vision, memory and behavior (American Stroke
Association, 2012). A stroke in the left hemisphere can affect sensory and motor skills of
the right side of the body, speech and language deficits, and memory (American Stroke
Association, 2012). Strokes in general can result in commonly observed motorperformance skill deficits that impact occupational performance including poor trunk and
postural control, lower extremity weakness and/or spasticity impacting balance, standing,
and walking, and upper extremity dysfunction (pain, edema, contracture, weakness, poor
motor control) (Gillen, 2006; Gillen, 2011). For the upper extremity alone, this can
impact reaching and manipulation of the affected limb, thus impacting bilateral hand
coordination for tasks such as opening containers, pouring water, and manipulating
medications.
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Clinicians routinely have access to a variety of motor assessments that ranges
from impairment-based such as the Fugl Meyer Assessment of Physical Performance
(FMA) (Fugl-Meyer, Jaasko, Leyman, Olsson, & Steglind, 1975), to performance-based
assessment such as Chedoke Arm and Hand Activity Inventory (CAHAI) (Barreca,
Stratford, Lambert, Masters, & Streiner, 2005). The FMA is a stroke-specific,
performance-based impairment screen. It was designed by a physical therapist to assess
motor functioning, balance, sensation and joint functioning in clients with post-stroke
hemiplegia (Fugl-Meyer et al., 1975). Over the years it has often been used as a gold
standard to measure other assessments against and the FMA has good evidence of
validity and reliability (StrokEngine, 2013b). Occupational therapists often use a shorter
version that measures the level of impairment of solely the upper extremity through
motor function, joint pain, joint range of motion and sensory function (StrokEngine,
2013b). Scores from the FMA relay the level of disability on a severity scale, and the
FMA is thus often used to assess recovery of physical impairment.
The CAHAI is a functional assessment that assesses the recovery of the arm and
hand affected by stroke (Barreca et al., 2005). The original CAHAI consists of “13
functional items that are non-gender specific, involve both upper limbs, and incorporates
a range of movements and grasps that reflect stages of motor recovery following stroke”
(StrokEngine, 2013c). It includes items such as: open a jar of coffee, dial 911, draw a line
with a ruler, pour a glass of water, wring out a washcloth, do up five buttons, dry back
with a towel, put toothpaste on a toothbrush, cut medium consistency putty, clean eye
glasses, zip up a zipper, place a container on a table, and carry a bag up the stairs
(Barreca et al., 2005). The CAHAI has a 7, 8, or 9 item version as well; all versions have
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demonstrated adequate validity and reliability (StrokEngine, 2013c). Outcomes from this
screen indicate the level of independence a client has with a specific task aiding in
treatment planning and assessing recovery. The CAHAI is well accepted by clients and
clinicians due to the use of real-life objects and scenarios thus strengthening the desire to
have a medication management capacity screen which uses a similar function-based
approach to assess a real-life skill.
Stroke and Medications
After sustaining a stroke, clients potentially have performance deficits in relation
to cognitive and/or physical skills; the combination of both can hinder safety and capacity
for medication management. Factors such as other disease processes, types of
medications being taken, and the demands of recovery and rehabilitation can additionally
impact the client’s function as well as stroke location (hemisphere or lobe), type of stroke
(embolic or hemorrhagic), number of days post-stroke, certain medications types, and
poor stress and sleep patterns can negatively impact cognition potentially impairing
function (Yassa, 2012).
Clients post-stroke generally are older, have comorbidities, may be taking a
higher number of medications and/or require a specific schedule of prescriptions
(Ostwald, Wasserman & Davis, 2006). Comorbidities can include depression,
hypertension, diabetes, congestive heart failure, high cholesterol and atrial fibrillation
(Ostwald et al., 2006). Complications during stroke recovery can include depression,
urinary tract infection, limb pain, and the possible use of tubes (for catheterization,
tracheotomies, or feeding) (Ostwald et al., 2006). Medications for clients post-stroke can
range from anti-coagulant, anti-platelet, anti-hypertensive, anti-diabetic, anti-depressants,
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anti-seizure, antibiotics, bowel regime medications, and pain reduction medications
(Furie et al., 2011; Ostwald et al., 2006). Medications such as antidepressants, beta
blockers (such as Propranolol), and barbiturates/benzodiazepines (such as Valium) and
analgesics (such as Morphine or Oxycodone) can mimic neurological disorders, and/or
impact brain functioning and performance (Yassa, 2012). The combination of
comorbidities and complications is associated with higher medication use, and in one
study by Ostwald et al., (2006) clients post-stroke were discharged with an average of 11
medications in five different drug classifications. Along with a potential for an increased
number of medications, these medications may also have precautions (e.g. take with
food), special instructions (e.g. storage), and side effects of which clients must be aware
(Ostwald et al., 2006). Recognizing the number of medications and the types of
medications a client is taking can be helpful for the occupational therapy practitioner to
better appreciate the client’s performance and its impact on medication management
capacity.
In summary, to safely manage medications, clients must be able to physically
manipulate their medications, such as the packaging and pills, and use higher level
cognitive skills to remember and follow their often complex medications and medication
routines. There are a limited number of performance-based assessments to assess a
client’s capacity to manage medication routines, especially for people with high risk
diagnoses such as stroke. In the following section of this literature review, a summary of
current medication management screens is presented. The weaknesses of a number of
these screens as medication management capacity screens will be presented along with
more in depth information about and comparison of the MMS and S5 will be presented.
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Medication Management Screens
In current healthcare practice, there are a variety of medication management
screens. As seen in Appendix A, some screens are used in specific settings, solely for
research purposes, or in specific disciplines. The few screens that are used in
occupational therapy often focus solely on cognition, such as the Cognistat or Mini
Mental State Exam. These tests were not designed to assess medication management
capacity, but rather the intrinsic skills that are necessary for medication management (e.g.
memory, attention). The sample of screens listed below (also in Appendix A) will be
further examined as follows.
The Self-Administration of Medication (SAM) is used by nurses to assess a
person’s competence to self-administer medications when used in the acute care setting.
This assessment uses interview and observation of patients (Manias, Beanland, Riley, &
Hutchinson, 2006). The Medication Management Ability Assessment (MMAA) is a
performance-based measure of medication management for patients with schizophrenia
using role-play. The MMAA is a modification of the Medication Management Test
(MMT) (Patterson et al., 2002); the MMT was initially designed to assess adaptive
strategies in patients with dementia with regard to medication management (Gurland et
al., 1994). It has since evolved to include the HIV population to assess ability to organize
HIV medications into pill boxes. It has been reported that use of the MMT is simple, but
that scoring is complex and not always clinically applicable (Farris & Phillips, 2008).
The Drug Regimen Unassisted Grading Scale (DRUGS) screen is reported to be an easyto-administer tool that assesses a highly functioning older adult’s ability in selfmedication; the screen assesses the ability to identify, access, dose and time their
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personal medication routine (Edelberg, Shallenberger, Hausdorff & Wei, 2000). The
Medication Management Instrument for Deficiencies in the Elderly (MedMaIDE) is
primarily used in research to assess medication adherence (e.g. compliance and
management) (Orwig, Brandt, & Gruber-Baldini, 2006). The MedTake Test assesses
understanding of dosage, indications, schedule, and safety through an interview of older
adults (Kaizer et al., 2010). The fairly new Self-Medication Assessment Tool (SMAT) is
a comprehensive tool used by pharmacists to assess deficits in self-management of
medications by looking at function, cognition, self-reported adherence, medication recall
and purposeful non-adherence (Irvine-Meek, Gould, Wheaton & Todd, 2010; IrvineMeek & Gould, 2011).
All the previously mentioned screens have been critiqued through numerous
research studies. Some of the mentioned assessments are profession specific (nursing or
pharmacy), population specific (older adults, clients with dementia or schizophrenia), or
rely on self-reports or interview for results. Furthermore, many studies did not define
medication management, raising the question: was the intent to study capacity or
adherence? Most of these screens have been found to be far removed from the actual
performance of medication management as these screens are mainly observation,
question/answer or paper-pencil based. Many of these screens have been critiqued to be
too time consuming or not applicable to a clinical setting as they do not provide
functionally relevant information. Moreover, these screens often lack important domains
such as communication and physical skills when assessing the capacity to manage a daily
medication routine for clients post-stroke as mentioned by Donovan et al., 2008, Kaizer
et al., 2010 and Robnett et al., 2007.
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New screening tools continue to be developed to address the increasing need in
occupational therapy practice for comprehensive medication management screens that
assess both cognitive and physical skills in a functionally relevant manner. Two such
screens are the ManageMed Screen© and the Self-Medication Safety Post Stroke Screen.
ManageMed Screen©.
Robnett et al., (2007) developed a quick portable standardized functional test, the
ManageMed Screen (MMS), to assess the capacity of adults 18 years and older to
manage a moderately difficult medication routine (e.g. discriminates amongst normal and
low functioning clients) (Robnett & Moyers, 2007). The MMS assesses medication
management capacity, an activity of daily living for adults. The MMS was developed by
occupational therapists for use by occupational therapists to serve as a quick screen to
provide a “snapshot of the client’s ability to comprehend information related to
prescription use” by utilizing four metacognitive questions, 32 questions addressing
reading, medication knowledge base, problem solving, short-term and prospective
memory, and calculations, and lastly a performance task to assess the client’s physical
and cognitive ability to set-up a weekly medication organizer (Robnett & Moyers, 2007,
p. 2).
When developing the MMS, authors collected data from a sample of convenience
of 33 nursing home residents who needed assistance with medication management and 34
community living elders who were independent with medication management. All were
tested with the MMS and 40 were also tested with the Cognistat. Exclusion criteria
include moderate to severe dementia; disease processes were not recorded (therefore
some participants may have been stroke survivors) (Robnett et al., 2007). The final
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segment of the test, setting up the pill organizer, was additionally tested on 72
pharmacists and seven pharmacy technicians in order to establish content validity of the
MMS. The authors found that participants tended to rate their ability to think and
remember higher than they actually performed, and age was found to be related to
performance. The test was able to differentiate the participants who were independent
from those who required assistance with medication management, and a norms table
based on age was developed (Robnett & Moyers, 2007). Results would suggest that
subjective reports of a client’s ability to manage medications may not be reliable,
especially if there is a cognitive limitation. Rather, objective measures of cognitive and
physical performance are needed for accurate results in regards to medication
management capacity.
As part of the development of the MMS, correlation between the MMS and
Cognistat scores was conducted; it was determined the MMS is similar to the Cognistat,
but the tests assess different aspects of cognition (Robnett & Moyers, 2007). The MMS
and Cognistat assess key cognitive domains of orientation, language, reading and writing,
numeric/calculation, visuospatial function, attention, and executive function
(reasoning/judgment) as mentioned in Donovan et al., 2008 and Stilley et al., 2010.
However the Cognistat does not thoroughly address limb praxis or physical performance
as does the MMS. The Pearson correlation coefficient showed moderate correlation (r =
0.696, p = .001), and inter-rater reliability was assessed and ranges were in the
satisfactory to high range (0.859 to 0.965) (Robnett & Moyers, 2007). Rasch analysis was
conducted to look at the degree of difficulty of items; the items in the ManageMed
Screen were deemed to be of moderate difficulty and without ceiling effect for detecting
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medication management capacity. The MMS is therefore a standardized test that has been
validated for adults over the age of 18; it is able to distinguish between adults who need
assistance and those who are independent. However, the MMS has yet to be studied
specially for use with clients with specific diagnoses or performance limitations, such as
stroke. The author acknowledges the need for further validity and reliability studies in
various client populations to ensure its effective use, however as the test is designed to
distinguish among clients who are independent and need assistance. Thus the MMS
would be an appropriate tool to use with clients post-stroke based on the performance
factors assessed (Robnett et al., 2007; R.Robnett, personal communication April, 1, 2013).
The MMS is available for commercial purchase online; the clinician is provided
with a thorough test manual, “three simulated pill vials (with candy imitation pills), a
mock prescription, three realistic medication information sheets, a pill organizer, the test
forms, and a magnifying glass” (Robnett et al., 2007, p. 11). As this test is standardized,
a norms table was developed on a second group of 100 independent adults to determine
age-related norms, and is found in the test manual (Robnett & Moyer, 2007).
Self-Medication Safety Post Stroke Screen.
Authors Kaizer et al., (2010) conducted a literature review to determine if any
medication management tools in existence could be used with clients post-stroke (the
MMS was not included in this review). Concluding “none were tailored to the multifaceted needs of the stroke population,” the author set out to develop the Self-Medication
Safety Post Stroke Screen (S5) to meet the needs of occupational therapy practitioners by
having a tool that can assess medication management capacity that is diagnosis specific
to stroke (Kaizer et al., 2010, p. 239). The development of the S5 was done in three
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phases: 1) a literature review of nine medication management tools, 2) the development
and draft of a new screening tool, and 3) pilot testing of the screen.
Nine tools were reviewed [Self-Administration of Medication (SAM), The
Medication Management Ability Assessment (MMAA), The Drug Regimen Unassisted
Grading Scale (DRUGS), Hopkins Medication Schedule, The Medication Management
Instrument for Deficiencies in the Elderly (MedMaIDE), Self- Medication Risk
Assessment Instrument, The Medication Management Tasks, Standardized Medication
task (SM task), and MedTake Test] as cited in Kaizer et al. (2010) and were found to
have limitations in their design and clinical use. The main limitations were that none of
the tools were standardized for clients post-stroke and none met the cognitive or physical
demands to be used for the stroke population as mentioned by Donovan et al., 2008 and
Kaizer et al., 2010. From this review, the authors identified factors that needed to be
included in a new screen for use with clients post-stroke; these included: memory,
orientation, physical ability, communication and planning an action (Kaizer et al., 2010).
Test items were then developed and a screen was drafted.
The authors had eleven stroke experts review the screen that included five
occupational therapists, one speech language pathologist, one neurophysiologist and one
pharmacist. These interviews aided authors to devise a final draft of the screen that was
then pilot tested on six participants who were purposively chosen. From a post-test
interview of the six participants, changes were made to the screen for clarification of test
items and expansion of client instructions.
The S5 includes basic orientation questions, the manipulation of medication
bottles, calculating medication doses, immediate and delayed memory recall tasks,
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manipulating a syringe (if appropriate for the client), completing visual recognition and
visual spatial tasks, problem-solving questions to assess cognition (orientation;
immediate and delayed memory recall), communication (comprehension; reading), motor
function, visual-perception, and judgment/executive functions/self-efficacy (Kaizer et al.,
2010; StrokEngine, 2013d). Preliminary testing was completed on a target population on
a sample of five subjects; test-rest reliability is still under study, however content validity
has been reported as satisfactory making it a potential valid and reliable screen
(StrokEngine, 2013d). Moreover, the S5 reflects some of the cognitive domains of
concern (memory, initiation, communication and planning) mentioned by Donovan et al.
(2008), Neupert et al. (2011), and Stilley et al. (2010), and the physical capacities
highlighted by Robnett et al. (2007). The S5 is the first known stroke-specific medication
management screen. The S5 is available free online for clinical use; however, the current
version is based on pilot testing only and thus has undergone only a preliminary
validation study by its authors (Kaizer et al., 2010). Clinicians are given a one page
instruction handout for kit assembly and a one page checklist for questions and scoring.
Summary
Occupational therapy practitioners need screening tools that will assess and
address capacity for medication management and that are objective, quantitative, valid,
reliable, administered with minimal training, easily and immediately scorable, brief,
small, portable, and non-threatening to the client to make them useful in the clinical
setting (Elliott & Marriott, 2009). Adults can be at risk for poor medication management
capacity due to potential comorbidities along with age-associated changes in function.
However, adult clients post-stroke are at even greater risk of difficulty with medication
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management due to changes in cognitive and physical functioning. After reviewing
various assessment tools there is no gold standard or widely accepted method or tool,
especially as many tools measure adherence patterns related to cognition rather than
capacity to manage medications. Additionally, stand-alone cognitive assessments can not
be used to assess medication management capacity. Traditional assessments as reviewed
in Donovan et al. (2008) and Kaizer et al. (2010) do not meet the needs for the stroke
population as they lack attention to key factors and domains related to cognition and
physical performance. Additionally many of the screens reviewed for this study are
paper-pencil assessments that are somewhat removed from the actual performance of
medication management. While the MMS was not specifically designed for use with
clients post-stroke, it has strong validity and reliability in which to discriminate among
adults who are independent with medication management and those who need assistance.
The S5 was designed to assess medication management capacity of clients post-stroke,
but continues to need further research to assess reliability, validity, and clinical
usefulness as its development was based on such a small selected group of participants.
This capstone study is a pilot study to begin the investigation of how the MMS compares
to the S5 for assessment of medication management capacity of clients post-stroke in
regards to consistency of scoring. Factors including scores and clinician feedback will be
use to assess their usefulness for used with clients post-stroke in a rehabilitation setting.
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Methodology
Research Design
This capstone is a mixed methods pilot study design including quantitative and
qualitative data collection and analysis. This study was approved by the IRB at Nova
Southeastern University and the IRB of HealthSouth Corporation (Appendix D, E).
Part I: quantitative data was gathered by clinicians trained by the primary investigator to
assess a client’s medication management capacity post-stroke utilizing two medication
management screens and a cognitive screen. The purpose was to compare consistency of
scores from the MMS, S5 and MoCA in relation to detecting medication management
capacity. Part II: qualitative data was obtained from the clinicians who participated in a
focus group interview after data collection was completed. The purpose of the focus
group was to gather information from the clinicians regarding their perceived usefulness
of the screens by discussing positive and negative aspects of each screens and their use in
clinical practice with clients who have sustained a stroke.
Participants
Clinician participants were recruited from New England Rehabilitation Hospital,
an inpatient rehabilitation hospital, in Portland, Maine (Appendix I, K). Clinicians were
used in Part I and II of this study. Clinicians included one male and two females with
clinical experience ranging from 3 to 15 years.
Client participants were recruited by clinicians during their rehabilitation stay at
New England Rehabilitation Hospital, an inpatient rehabilitation hospital, in Portland,
Maine. Clients were recruited based on specific inclusion/exclusion criteria (Appendix I,
J). Five clients participated in the study, including three females and two males with a
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mean age of 72.6 years. Twenty percent of client participants had a right hemispheric
stroke of embolic origin, days post-stroke ranged from 9 to 17 with a mean of 11.6 days,
and clients were taking medications ranging from 4 to 13 medications with an average of
9.8 medications at the time of screen administration. For visual deficits, 40% were
reported to have a deficit (field cut or neglect) (client specific demographics also seen in
Table 1 below).
Table 1. Client Participant Demographics
______________________________________________________________________
Client Age
Gender
Stroke Type & Days Post Number of
Visual
Location
Stroke
Medication Deficits
1

80

Male

Embolic, Left
hemisphere

9

10

Neglect &
field cut

2

67

Male

Embolic, Left
hemisphere

8

12

Other

3

86

Female

Unknown, Right
hemisphere

17

13

None

4

64

Female

Embolic, Left
hemisphere

15

10

None

5

66

Female

Embolic, Left
hemisphere

9

4

None

Additional data were collected on each subject including hand dominance, types
of medication taken in specific categories, self rated score for level of stress and
difficulty with sleep on a scale of one to five (one being no problem with stress or sleep
and five being high stress or severe difficulty with sleep) (see Table 2).
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Table 2. Client Participant Demographics - Secondary Data
_____________________________________________________________________
Client
Hand
Medication
Level of
Difficulty
Dominance
Type
Stress
with Sleep

1

Left

Beta blockers
Analgesics

2

1

2

Left

Beta blockers
Analgesics

4

2

3

Right

Beta blockers
Analgesics

2

1

4

Right

Beta blockers

1

1

5

Right

N/A

3

2

Instrumentation
Part I: Instruments used in data collection include the ManageMed Screen (MMS),
the Screening for Self-Medication Safety Post Stroke (S5), and the Montreal Assessment
of Cognition (MoCA) (Robnett et al. 2007; Kaizer et al., 2010; Nasserdine et al. 2005)
(Appendix F).
The MMS has 30 questions and performance tasks to assess “reading, medication
knowledge base, problem solving, short-term and prospective memory, and calculations”
(Robnett & Moyers, 2007, p. 2). The MMS is standardized and has strong validity and
reliability. A sample question for reading, medication knowledge base, problem solving
is “If this [prescription A] were a prescription from you doctor, would it be safe to take?”
The client is given a prescription bottle with printed label information to review; the
client is to note the date the medication expired. Other questions related to problemsolving, short-term memory, calculation and physical skills include “Can you open these
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containers? Count the number of pills. How long will these pills last if taken as
prescribed?” Lastly, one task in particular requires the client to successfully utilize all
cognitive skills and assesses physical skills when the patient is asked to set up a pill
organizer using three medications based on instructions on each prescription bottle while
recalling that their meals are taken at 8am, noon and 5:30pm. Slots in a plastic organizer
must be opened and the client puts in the correct number of pills at the correct times.
Performance on this screen is scored on a 0 or 1 scale with 0 indicating unable to perform
or performed incorrectly and 1 as performed correctly. The maximum score one can
obtain is 39 points; the client’s score can then be compared to age-related norms
developed by the authors.
Potential impairments that can be distinguished with use of this screen include
decreased vision, decreased prospective memory, decreased recognition, decreased safety
awareness, decreased attention to detail, decreased physical ability, decreased calculation
skills, decreased retrospective memory, decreased organizational skills, and decreased
insight (Robnett & Moyer, 2007). The findings of these impairments would indicate poor
medication management capacity and also provide areas for occupational therapist to
focus either rehabilitation or remediation intervention strategies.
The S5 has 16 questions on a checklist to assess basic orientation, the
manipulation of medication bottles, calculating medication doses, immediate and delayed
memory recall tasks, manipulating a syringe (if appropriate for the client), completing
visual recognition and visual spatial tasks, and problem-solving questions to assess
cognition (orientation; immediate and delayed memory recall), communication
(comprehension; reading), motor function, visual-perception, and judgment/executive

MEDICATION MANAGEMENT CAPACITY POST-STROKE

35

functions/self-efficacy (Kaizer et al., 2010; StrokEngine, 2013d). A sample question
which addresses calculation, visual recognition, and problem solving includes ‘If you
have to take 2 pills in the morning and 2 at night, show me how you would group the
pills’ after providing an open bottle with 8 identical white disc-shaped pills. To assess
physical skills, some test items include providing a syringe without a needle and asking
the client to demonstrate how to inject their medications or providing the client with a
bottle of liquid medication and asking them to “Open the bottle and pour out 10ml of the
liquid into this cup.” Scoring is completed by indicating if the task was done correctly by
checking Yes or No boxes beside each question. The score is out of 16 questions; in
general a higher score of more Yes responses would indicate less difficulty with
medication management. More importantly, the screen offers specific areas of concern
when a question is marked as No that can be addressed in occupational therapy
intervention. Scoring criteria was not developed beyond a yes/no checklist. For the
purpose of this study, questions marked yes were counted as 1 point. If a client scored a
14, 15 or 16 on the S5 this equated ‘normal’ performance capacity; if a client scored 10 to
13 this equated ‘questionable’ performance capacity, and if a client scored 9 or less, this
equated ‘poor’ performance capacity with medication management.
For the purpose of this pilot study, the MoCA was also used to assess the clients’
cognition and explore the relationship with medication management capacity. The MoCA
is a performance-based screen to assess cognitive skills which contains 16 test items that
examine attention and concentration, executive functions, memory, language,
visuoconstructional skills, conceptual thinking, calculations, and orientation (Nasreddine,
2013). A sample question to assess attention, concentration, executive function,
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visuoconstructional skills, and conceptual thinking is drawing a clock; the client is asked
to draw a clock, place all numbers in the clock and set the time to five past four
(Nasreddine, 2013). The client is scored based on contour of the clock, correct sequence
and placement of numbers in the clock along with correct placement of the hands of the
clock. Points are given based on correct answers/performance of task. Another sample
item that assesses attention and calculation is asking the client to subtract serial 7s
starting with number 90; points are given based on correct subtractions. The entire
assessment is based out of 30 points with 26 points or greater indicting normal cognitive
performance, thus any score under 26 should be investigated further (1 point is given to
the final score if the client has less than 12 years of formal education) (Nasreddine, 2013).
The MoCA has undergone years of research and studies have consistently demonstrated
excellent validity and reliability (StrokEngine, 2013e).
This research project required two kits for the MMS, two kits for the S5 and two
sets of printed instructions for the MoCA that were provided by the primary investigator.
Two kits of each were made to avoid delay in data collection should some testing occur
simultaneously by one or more clinicians. A copy of the testing materials can be found in
Appendix F. Beyond test scores, secondary information was collected to further explore
client performance and relationships between screen scores or other factors. Information
such as client age, gender, hand dominance, stroke hemisphere location, stroke type,
number of days post-stroke, number of different medications and if specific medication
types were used, presence of visual impairment, self-rating on perceived level of stress
and difficulty with sleep, and total number of minutes needed for testing were collected.
Specific medication types, presence of visual impairment, self-rating on perceived level
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of stress and difficulty with sleep is interesting secondary data as studies show that
specific medication, poor sleep and stress impact cognitive performance, and visual
impairment can also impact the ability to performance certain tasks on these screens
(Yassa, 2012). As a means to collect and record data from 3 assessment tools, a data
collection sheet was devised for clinicians to record information into one location
(Appendix G).
Part II. The instrument that was used in the guided focus group for clinician
participants was an open-ended interview guide of 10 questions devised by the primary
investigator. The questions were intended to evoke dialogue among the clinicians to
solicit feedback regarding their impression of the screens, the value of information
obtained from testing, advantages or disadvantages of each screen, scoring discrepancies,
and overall usefulness the screens. A sample question includes “share your impression or
feedback on the administration of each test, such as ease of setup, clarity of instructions,
items in test kits, questions asked etc.” The question guide can be found in Appendix H.
Procedure
Recruitment.
With approval from the IRB at HealthSouth and IRB at Nova Southeastern
University (Appendix D, E), clinician participants were recruited to participate in this
capstone pilot study during a 4 week period. A presentation was provided to the inpatient
occupational therapy department to recruit interested clinicians. Emails were exchanged
as needed to clarify inclusion criteria and set-up a time to consent their participation.
Inclusion criteria included: one year experience on the “Stroke Team” at the inpatient
rehabilitation center as an occupational therapist, show interest in using medication
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management capacity screens to better serve their clients, be willing to participate in
training sessions, test clients for data collection [part I], and participate in a focus group
[part II]. As clinicians were part of data collection procedures for this research study, they
were included as research assistants for this study in the IRB protocol and were required
to complete the CITI training and adhere to the approved IRB protocol.
Client participants were patients recruited from New England Rehabilitation
Hospital (an inpatient rehabilitation center in Portland, Maine) during a 6 week period.
Five of seven clients recruited consented to participate in the study. Participants were
recruited based on the following inclusion/exclusion criteria: cognitively intact to consent,
adult with the diagnosis of stroke, taking daily prescription medication(s), without
moderate to severe receptive or expressive aphasia (4 or greater on functional
independence measure (FIM) for comprehension and expression), able to read or write in
English, and the participant was 72 hours from discharge from acute rehabilitation.
Clients were flagged by the rehabilitation director and occupational therapy clinical
leader at New England Rehabilitation Hospital when the client was anticipated to be
discharged, and were presented with the study. They then determined their interest in
participating. Clients were provided with written information and consent forms to
participate (see Appendix I, J). A mutually convenient time for testing was scheduled
based on client’s consent. The study was approved for 25 participants.
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Training.
Clinicians were recruited from the New England Rehabilitation Hospital and
participated in four hours of training prior to client recruitment and data collection. Prior
to direct training, clinicians were provided with a packet of information detailing the
research study’s introduction, purpose of research, overview of tests and target
population and overview of the commitment for participation (e.g. training, data
collection, focus group participation). Four clinicians consented to participation in the
study, and three were able to complete all trainings and collect data. Clinicians were also
provided with sample test packets of the MMS, S5, and MoCA, and test kits to
familiarize themselves with these prior to training. The four hours of training (two
sessions of two hours each) were scheduled based on staff availability and rehabilitation
director approval for date and time of day.
The first session was devoted to introduction, practice, and competency testing to
establish inter-rater reliability for the MoCA. An informal presentation by the primary
investigator was given, along with supervised practice between clinicians. To establish
inter-rater reliability, a clinician tested the primary investigator who role played a client.
The session was observed by the participating clinicians for scoring. The primary
investigator then assessed inter-rater reliability based on each question and overall score
for the assessment.
The next two hour session consisted of the same format but was for the MMS and
S5. Again an informal presentation by the primary investigator and co-investigator (R.
Robnett) was given, along with supervised practice between clinicians. To establish interrater reliability, the co-investigator tested the primary investigator who was again role
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playing a client. The clinicians observed and scored on an individual basis. Score sheets
were reviewed after these training sessions, but before participant data collection. An
acceptable level of inter-rater reliability was established at 80% agreement of each test
(Tickle-Degnen, 2008). For the MoCA, there was 100% inter-rater reliability, for the
MMS there was 96.875% inter-rater reliability and for the S5 there was 91.964% interrater reliability (Appendix B). For any one item that was below 80% inter-rater reliability,
the question and scoring method was reviewed with clinicians for clarification. Inter-rater
reliability did not need to be reestablished for these test items as the criteria was to have
an overall inter-rater reliability of 80% for the entire test score.
Clinicians were also trained in the use of the de-identified data collection sheets
(Appendix G) and procedures for data storage during the study were established. Once
clinicians completed their screen training and CITI computer training for human research,
amendments were sent to IRB with their names to be added to the protocol as research
assistants. Approval was obtained to add clinicians as research assistants enabling the
start of data collection from clients (Appendix L).
Data collection part I.
Data collection lasted 6 weeks for a minimum of five client participants. Test
packets (including de-identified data sheets, instructions for the MoCA, and score sheets
for the MMS and S5) were made available by the primary investigator. Prior to testing,
clinicians gathered basic information about the participant from the medical chart and
indicated the information on the Data Collection sheet (Appendix G). Clients were given
information about the assessment (e.g. purpose, duration) by the trained clinicians to
confirm consent and to remind the client the assessment could be stopped at any time for

MEDICATION MANAGEMENT CAPACITY POST-STROKE

41

any reason. When participants consented, they signed the form and began testing. The
goal for the screening was for clients to complete them all in one day in a quiet,
designated area.
Testing commenced per testing and manual instructions. Information such as age,
gender, hand dominance, stroke location/type, days post-stroke, medication questions,
presence of visual impairment and ratings for stress and sleep were always completed
first and in numerical order. Questions for the screen score of the MoCA, MMS, and S5
(questions 13, 14, 15) were not always listed in the same numerical order on each data
collection sheet to enable random order of testing of the screens between clients.
Clinicians were told to complete each screen in the order in which they were listed on the
data sheet and not necessarily numerical order for questions 13, 14, 15.
Blank test packets were kept in labeled folders with instructions in the
rehabilitation director’s office; completed test packets were kept in a secured drawer in
the locked office of the rehabilitation director for the duration of the study. Once data
collection was completed, the primary investigator collected the data sheets ensuring no
participant identifier/confidential information was on the data sheets. This data was then
stored in the co-investigators locked office at the University of New England, Portland,
Maine.
Data collection part II.
After the clinicians completed a minimum of five assessments and six weeks from
the start of data collection, the clinicians participated in a 1 hour and 30 minute focus
group interview. The interview took place in the office of the clinical leader at New
England Rehabilitation Hospital of Portland, Maine at a convenient time for the clinicians.
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Due to the small sample size of clinicians, the interview was transcribed verbatim by
hand by the primary investigator during the interview process. The primary investigator
facilitated the discussion with focus on: clinician feedback on administration of each
screen (ease, setup, instructions etc.), value of data obtained from the screens, advantage/
disadvantage of each screen, and usefulness of the screens to clinical practice. The
interview guide can be found in Appendix H.
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Data Part I
Primary Data
As seen in Table 3, compared to the normative scores by age, client 1 scored
within one standard deviation above the mean score for the MMS, ‘normal’ performance
on the S5, and below the mean score for the MoCA. Client 2 scored well above one
standard deviation of the mean score for the MMS, ‘normal’ performance on the S5, and
above the mean score for the MoCA. Client 3 scored within one standard deviation below
the mean score on MMS, ‘questionable’ performance on the S5, and at the mean for the
MoCA. Client 4 scored within one standard deviation below the mean score for the MMS,
‘normal’ performance on the S5, and below the mean for the MoCA. Client 5 scored
within one standard deviation above the mean score for the MMS, ‘normal’ performance
on the S5, and at the norm for the MoCA.
Table 3. Client Scores on MMS, S5, and MoCA
___________________________________________
Client
MMS
S5**
MoCA***
(mean +/- SD*)

1

30

15

21

15

28

13

26

15

19

14

26

(29 +/- 3.39)

2

35
(29 +/- 3.39)

3

26
(29 +/- 3.39)

4

32
(34 +/- 3.29)

5

31
(29 +/- 3.39)

____________________________________________
*MMS age norms based on client age +/- standard deviation (SD) (Robnett & Moyers, 2007)
**S5:14, 15 or 16 = ‘normal’ performance capacity;
10 to 13 = ‘questionable’ performance capacity;
9 or less = ‘poor’ performance capacity
***MoCA: 26 or better = normal performance
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Secondary Data
From the secondary data collected, consistency of mean scores for age, gender,
hand dominance, right versus left hemisphere stroke, embolic versus hemorrhagic stroke
and medication type between the MMS, S5 and MoCA were compared.
Age, gender and hand dominance.
The mean age for client participants was 72.6 years; as seen in Table 4, the
youngest client at age 64 scored below the norm on the MoCA, but had normal
performance for the MMS and S5. The oldest client at age 86 scored normal performance
for the MMS and MoCA, but had questionable performance on the S5. In Table 7, values
for nonparametric two-tailed test of Spearman’s rho correlations was conducted on the
client age and screen scores can be found indicating no consistent relationship.
Table 4. Client Scores by Age on each Screen
Client

MMS

S5**

MoCA***

Age

15

21

80

15

28

67

13

26

86

15

19

64

14

26

66

(mean +/- SD*)

1

30
(29 +/- 3.39)

2

35
(29 +/- 3.39)

3

26
(29 +/- 3.39)

4

32
(34 +/- 3.29)

5

31
(29 +/- 3.39)

*MMS age norms based on client age +/- standard deviation (SD) (Robnett & Moyers, 2007)
**S5:14, 15 or 16 = ‘normal’ performance capacity;
10 to 13 = ‘questionable’ performance capacity;
9 or less = ‘poor’ performance capacity
***MoCA: 26 or better = normal performance
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As seen in Graph 1 there was no notable difference in performance of male and
female in all three screens. The mean for males on the MoCA was 24.5 and females were
23.6 (26 or better = normal performance); the means for males on the MMS was 32.5 and
females was 29.6 (see Table 3 for age norms by client); and the means for males on the
S5 was 15 and females was 14 (14, 15 or 16 = ‘normal’ performance capacity; 10 to 13 =
‘questionable’ performance capacity; 9 or less = ‘poor’ performance capacity). By means
alone, both males and females scored below the norm on the MoCA, within age norms on
the MMS and ‘normal performance’ on the S5 suggesting no notable difference in
performance. Similarly, there were no notable differences in scores between individuals
with right hand dominance and left hand dominance as that two male clients were left
handed and the three females were right handed.
Graph 1. Mean Scores of Each Screen by Gender and Hand Dominance
_______________________________________________________________________
35

Screen Score

30
25
20

Male/Left
Female/Right

15
10
5
0
MoCA

MMS

S5

______________________________________________________________________
Stroke location and type of stroke.
In Graph 2 below, right versus left hemisphere stroke comparison revealed the
client with a right hemisphere stroke scored a mean of 26 on the MoCA (normal
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performance), 26 on the MMS (normal performance) and a 13 on the S5 (‘questionable’
performance). The remaining clients had a left hemisphere stroke and scored a mean of
23.5 on the MoCA (below norm), a 32 on the MMS (normal performance) and a 14.75 on
the S5 (‘normal’ performance). The consistency that is presented here is that the client
with a right sided hemisphere stroke had ‘questionable’ performance on the S5 when
compared to the other clients with a left hemisphere stroke, and the clients with a left
hemisphere stroke performed below the norm on the MoCA. The client with the right
sided hemisphere stroke was right handed, thus should have had intact motor skills of
his/her dominant hand to complete the tasks but may have some mild difficulty with
memory impacting his/her performance on the S5 (American Stroke Association, 2012).
The clients with a left side hemisphere stroke were split 50/50 with being right hand
versus left hand dominant, thus the clients who were right handed may have had some
difficulty with motor tasks and/or mild speech, language or memory deficits impacting
performance (American Stroke Association, 2012).
The means of each screen are the same when comparing stroke location to stroke
type as the one client who had a right hemispheric stroke from unknown origin. The four
remaining clients who had an embolic stroke where also the clients who had a stroke in
the left hemisphere (thus the same distribution of right and left handed comparisons
above). The only consistency seen here is the clients with an embolic stroke (left
hemisphere) scored lower than the client with the stroke of unknown origin on the MoCA,
but higher on both the MMS and S5.
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Screen Score

Graph 2. Mean Scores of Each Screen by Stroke Location and Type
________________________________________________________________________
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Days post stroke.
As seen in graph 3, when graphing client performance on all screens by clients
based on days post-stroke, the client with most days post-stroke (client 3) performed at
the norm for the MoCA and MMS, but ‘questionable’ performance on the S5. The client
with the least days post-stroke (client 2) performed ‘normal’ all three scores. Clients 1
and 5 with nine days post stroke had normal performance on the MMS and S5, but Client
1 scored poorly (below the norm) on the MoCA (similar performance to client 4). There
does not appear to be a relationship between days post-stroke and performance from each
screen, except that clients with fewer days post-stroke had overall better performance.
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Graph 3. Client Performance Based on Number of Days Post-Stroke
________________________________________________________________________
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Number of medications.
While this study was not investigating clients’ abilities to manage their own
personal medication routine, data on the number of medications clients were taking at the
time of testing (Graph 4) was obtained for comparison and to demonstrate the high
number of medications clients post-stroke must take and the implications on health and
safety that poor medication management capacity can mean for these clients. In Table 7,
values for nonparametric two-tailed test of Spearman’s rho correlations was completed
using the average number of medications (9.8) against each client’s screen score
indicating no consistent relationship between performance and the number of medications
the client was taking in this study.

MEDICATION MANAGEMENT CAPACITY POST-STROKE

49

Number of
Medications

Graph 4. Number of Medications Taken by Client Participants
_____________________________________________________________________

Medication types.
From secondary data collection, clinicians were asked to indicate if the clients
were prescribed antidepressants, beta blocker, barbiturates/benzodiazepines or analgesics
(as these can impact cognitive performance). Client 1, 2, 3 took both beta blockers and
analgesics, client 4 took only analgesics, and client 5 took no medications in these
categories. From Table 5, the clients taking beta blockers and analgesics on average
scored higher than the one client taking beta blockers alone for the MoCA and MMS, but
slightly less than the one client not taking any medication in those categories. The clients
taking beta blockers and analgesics scored lowest on the MMS, and near the same value
on the S5 as the client not taking medications in these categories. The one client taking
beta blockers alone scored best on the MMS and S5 but worse on the MoCA. The final
client not taking any medicines in these categories scored highest on the MoCA but
average on the MMS and S5. These variations do not support any type of relationship,
except that clinicians should be aware of clients taking beta blockers as this does seem to
impact cognition as seen by the score of 19 below for the MoCA.
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Table 5. Mean Scores of Screens by Medication Category
Beta blockers and
Analgesics

Beta Blockers Only

No Medications in
these Categories

MoCA

25

19

26

MMS

30

32

31

S5

14.3

15

14

Visual impairment.
Clinicians were asked to indicate by reviewing the client’s medical record if the
client who was participating in testing had any of the following: visual neglect, field cut,
cataracts, glaucoma or other. Of the five clients, client 1 was reported to have a visual
impairment of left neglect and a left field cut. Clients 3, 4, and 5 reported having no
visual impairments and client 2 had ‘other’ marked but not identified. Scores and
clinician feedback did not indicate the impact of these visual deficits on performance.
Stress and sleep post-stroke.
In review of client participant secondary data in regards to self-perceived level of
stress and difficulty with sleep post-stroke, a five point Likert scale was used (1 = no
problem, 5 = severe problem). Sixty percent of clients reported little to no stress (less
than a score of three for three of the clients) since their strokes, and 100% reported little
to no difficulty with sleep since their stroke (less than a score of two for all clients)
(graph 5). There does not appear to be a consistent relationship between stress, sleep or
performance on these screens.
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Rating Scale

Graph 5. Client Participant Rating of Stress and Sleep
________________________________________________________________________

Testing time.
The average time to complete the testing was 72 minutes (which included all three
assessments completed in one sitting. In Table 7, values for nonparametric two-tailed
test of Spearman’s rho correlations was conducted on the average time of testing (72
minutes) against each screen indicating no relationship in this study.
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Results Part I
Using visual comparison of data and statistical data analysis presented in the
above sections, the question: “How consistent are the ManageMed Screen (MMS) and
the Screening for Self-Medication Safety Post Stroke Scale (S5) scores for assessing
capacity in medication management?” can be answered by reviewing data in Table 6.
Overall, all clients scored within their age norms on the MMS, and all but client 3 scored
‘normal’ performance capacity on the S5. Using the Statistical Package for Social
Sciences (SPSS – version 20), each test score were correlated using nonparametric twotailed test of Spearman’s rho correlations. The MMS score was compared to the S5 score
and was found to be statistically non-significant (r=.671, p=.215).
Table 6. Score Comparison of the MMS and S5
____________________________________________________________
Client
MMS Score
S5 Score**
(mean score +/- SD)*

1

30

15

(29 +/- 3.39)

2

35

15

(29 +/- 3.39)

3

26

13

(29 +/- 3.39)

4

32

15

(34 +/- 3.29)

5

31

14

(29 +/- 3.39)
*MMS age norms based on client age +/- standard deviation (SD) (Robnett & Moyers, 2007)
**S5:14, 15 or 16 = ‘normal’ performance capacity;
10 to 13 = ‘questionable’ performance capacity;
9 or less = ‘poor’ performance capacity

When comparing the client’s performance on the MMS to the S5, the trend
appears to be the clients who scored the highest on the MMS also scored highest on the
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S5 (e.g. Clients 2 and 4 in Table 6). However, this pattern is not consistent as clients 1,
3and 5 also performed within the norm on the MMS and clients 1 and 5 scored 14 or 15
on the S5 suggesting ‘normal’ performance capacity. Nonetheless, client 3 who scored
the lowest on the MMS (but still within age norms) also scored the lowest on the S5
(‘questionable’ performance capacity). This pattern does not suggest a true pattern of
consistency between the MMS and S5 scores for higher scores, but was able to detect
lower scores consistently.
When looking at secondary data in which other factors are considered in regards
to mean scores of the screens we find the following (see Table 7-*using nonparametric
two-tailed test of Spearman’s rho correlations):
1.) there are no age* differences between screens,
2.)there are no notable differences in scores between gender and hand dominance,
3.) a client with right sided hemisphere stroke had ‘questionable’ performance on the S5
when compared to the other clients with a left hemisphere stroke; clients with a
left hemisphere stroke performed below the norm on the MoCA when compared
to the client with a right sided hemisphere stroke (graph 2),
4.) clients with an embolic stroke scored lower than that of the client with the stroke of
unknown origin on the MoCA, but higher on both the MMS and S5 (graph 2),
5.) clients with lesser days post-stroke on average had ‘normal performance’ on all
screens (graph 3),
6.) there are no differences between number of medications* and screen scores (graph 4)
7.) a client taking beta blockers alone scored the lowest on the MoCA suggesting this
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medication category does seem to impact cognition – thus performance on
cognitive screens (Table 5),
8.) there is no significance with visual impairments on performance between clients,
9.) there is no significance regarding ratings of stress and sleep (graph 5), and
10.) there is no significance among duration of time* and screen.
Just as the nature of stroke leads to variable presentations and outcomes among
clients, so does it appear that the only true comparative relationship of the MMS and S5
based on this sample, is that the MMS was consistent with the S5 in regards to
identifying the client who consistently scored the lowest on the MMS and S5 (client 3)
which is where occupational therapy would need to provide intervention.
Table 7. Spearman’s Rho Correlations of Secondary Data
________________________________________________________________________
Correlation Coefficient
Significance*
Age vs. MMS

.-700

p = .188

Age vs. S5

-.447

p = .450

Number of Medications
vs. MMS

-.205

p = .741

Number of Medications
vs. S5

-.229

p = .710

Number of Medications
vs. MoCA

.368

p = .542

Time vs. MMS

.791

p = .111

Time vs. S5

.412

p =.490

Time vs. MoCA

-.216

p = .727

*significant is p =.001, thus no relationships of significant value in this study
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To answer the second research question, “How consistent are the ManageMed
Screen (MMS) and the Screening for Self-Medication Safety Post Stroke Scale (S5)
scores compared to the Montreal Cognitive Assessment (MoCA) for assessing cognition
as an indicator for capacity in medication management?” using visual comparison of data
and statistical data analysis the data in Table 3 (re-inserted here from page 44) was
reviewed.
Table 3. Client Scores on MMS, S5, and MoCA
___________________________________________
Client
MMS
S5**
MoCA***
(mean +/- SD*)

1

30

15

21

15

28

13

26

15

19

14

26

(29 +/- 3.39)

2

35
(29 +/- 3.39)

3

26
(29 +/- 3.39)

4

32
(34 +/- 3.29)

5

31
(29 +/- 3.39)

___________________________________________
*MMS age norms based on client age +/- standard deviation (SD)
(Robnett & Moyers, 2007)
**S5:14, 15 or 16 = ‘normal’ performance capacity;
10 to 13 = ‘questionable’ performance capacity;
9 or less = ‘poor’ performance capacity
***MoCA: 26 or better = normal performance

When comparing client scores from the MMS and the MoCA, the general trend
was a client who scored normal performance on the MoCA also scored ‘normal’
performance based on age for the MMS (e.g. Client 2, 3, 5 in Table 3). Clients who
scored below the norm on the MoCA, scored within one standard deviation on the MMS
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still indicating ‘normal performance’ (e.g. Client 1, 4 in Table 3). There is no consistency
between the MoCA and MMS.
When comparing the MoCA to the S5, we find clients 1 and 5 who scored below
norms on the MoCA scored within ‘normal’ performance on the S5; conversely, client 3
who scored ‘questionable’ performance on the S5 scored at the norm on the MoCA.
There does not appear to be a consistent relationship between the S5 and the MoCA.
Using Statistical Package for Social Sciences (SPSS – version 20), the test scores
for the MMS and MoCA were correlated using nonparametric two-tailed test of
Spearman’s rho correlations (Table 7). The MMS score was correlated to the MoCA
score and was not found to be significant at a value of .205 with p=.741. The S5 score
was also correlated to the MoCA score using SPSS and was found to have a nonsignificant value of -.287 and p=.640.
From the comparison of the both the MMS and S5 to the MoCA for consistency
of scoring, we can conclude based on this sample, that there is not a consistent
relationship with scores for medication management capacity and cognition. Normal
performance based on norms of the MMS does not indicate ‘normal’ performance on the
MoCA, much like ‘normal’ performance on the S5 does not indicate ‘normal’
performance on the MoCA. However, the MMS and S5 were similar is scoring in regards
to indicating the same client who scored the lowest on both perhaps suggesting the
screens are able to detect those who have ‘normal performance capacity’ versus those
who have ‘poor performance capacity’ for medication management. However, any
relationships or trends noted must be interpreted with the utmost caution.
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Data Part II
Thematic qualitative analysis from the transcribed focused group data was
completed for data analysis of part II. The process used the following steps as described
by Creswell (2009):
1. Organize and prepare thorough transcription of notes
2. Initial processing for general sense of themes, phrases, keywords
3. Coding of themes throughout transcript manually
4. Discussion of any found patterns or themes that have emerged
5. Analysis and interpretations of themes
6. Recommendations related to the findings
The primary investigator conducted and transcribed verbatim clinicians’
responses during the focus group. Questions can be found in Appendix H.
Thematic analysis of all 10 questions and answers led to the development of
general themes that enables this data presentation. Theme A (questions 1 and 3) entails
clinician feedback on usefulness of the screens via administration, ease of setup, clarity
of instructions, test kit assembly/use and advantages/disadvantages of each screen.
Theme B (questions 2, 4, 5, 6, 8 and 9) relates the use of the screens in clinical practice
via the value of the data collected for treatment planning and discharge recommendations,
and clinicians’ impression with the screen’s ability to differentiate adequate from
inadequate medication management skills. Theme C (questions 7 and 10) relates to the
clinicians preference of screen for future use and the subjects’ responses to testing.
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Theme A: Usefulness of the Screens
Usefulness was defined to the clinicians as being accurate, efficient and practical
to their work setting and clinical practice. Clinicians did not experience first hand how to
obtain or put together their testing kits due to the nature of the study and requirements for
testing prior to data collection. However, clinicians were made aware that the MMS
comes assembled but needs to be purchased, while the S5 is free but must be assembled
by the practitioner. A clinician stated the MMS “comes in a complete kit which is helpful
[efficient and practical] for a busy work setting,” while the S5 requires clinicians make
their own kit adding a burden to the clinician and can impact accuracy as the screen is
“less standardized”. Both kits have “items/pieces that could easily get lost” especially as
more clinicians start using the kits in practice which could cause efficiency challenges
(e.g. locating all testing items or replacing missing items) in the future due to the fastpaced work setting.
To collect more information on usefulness, clinicians were asked to state
advantages and disadvantages of each screen where advantages would relate to being
useful (accurate, efficient, practical) in clinical practice and the disadvantages would
make the screen less useful. Advantages to the MMS screen as identified by the clinicians
included: the screen is “more relevant and practical to every life,” test “items are
realistic,” “good variety of questions and test items,” “generally has easy to follow
instructions for clinician and client,” and it is “standardized with norm values.”
Disadvantages to the MMS included: “it’s time consuming” “difficult to score during
administration,” and “pill box labeling for scoring is not consistent with instructions.”
The disadvantages make the MMS less useful in practice to clinicians; however clinician
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consensus from the focus group was that advantages outweighed the disadvantages while
the MMS lacks efficiency in time to conduct and score the test, it contained practical test
items, and had easy instructions to follow enabling the clinician to be more accurate with
testing and scoring.
Advantages to the S5 screen regarding usefulness (accurate, efficient, practical)
included: “quick, uses easily available items to put the kits together, and has a variety of
bottles and pills” and is “easy to score and administer at the same time.” “It’s a good tool
for clients who may be resistive to testing or easily frustrated.” Disadvantages to the S5
included: “too simple and too subjective in scoring,” “no way to accurately score or
interpret results,” “does not provide enough information,” and it does not appear to be
“standardized and has no norms values.” These disadvantages make the S5 less useful in
practice to clinicians in regards to being accurate and therefore a less practical screen to
use; however clinicians consensus from the focus group was S5 has its place in practice
for the right client, such as one who may be resistive to more formal testing like the
MMS. Clinicians did not rule the S5 out from their clinical practice, but felt the MMS
may be more generally more useful.
Clinicians were asked to share feedback on their impressions of the MoCA. They
reported: “the purpose, directions and scoring is easily understood,” but the MoCA is a
screen typically used by speech therapy in this setting, “but now it’s nice to understand
the screen better and be able to compare scores,” and “it’s standardized.” However,
clinicians reported the MoCA “does not relate to function,” “can be too long and abstract
for some clients,” and “not a good screen if the client is aphasic.” Clinicians agreed that
the MoCA would not be a useful tool for assessing medication management capacity as it
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would not accurately screen the client’s skills; however, it is a worthwhile tool to have
access to in the practice setting to be able to offer a cognitive screen and it does enable
interdisciplinary care.
Theme B: Applicability to Clinical Practice
Clinicians were asked to discuss the applicability and value of the data obtained
from the screens and how it would impact clinical practice in regards to treatment
planning and discharge recommendations. Clinician responses included: “results were an
eye opener for me [clinician] and client as it identified areas of need or risk,” “enabled
better discharge planning,” and the screens were very “applicable to this setting.” With
these tools “testing will help the entire rehabilitation team be more proactive with
discharge planning by identifying specific areas to assess in a standardized approach,”
and “tools such as these can help our department have a more formal process for client
teaching and programs around medication management.” One clinician felt that if these
screens were done earlier in the rehabilitation process “referrals to speech could be made
to help address cognition should they score poorly on the MoCA.” The theme that
emerged suggests that these screens are applicable to clinical practice in identifying
clients who may have difficulty with medication management. This information informs
accuracy of treatment planning, discharge recommendations and referrals to other
disciplines.
Clinicians stated the clients generally performed as anticipated based on their
functional performance of activities of daily living. However, one client (client 4) who
was doing very well with self-care and mobility performed poorly on the MoCA and was
receiving speech therapy for cognitive deficits. While this client had normal performance
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with the MMS and S5, the fact that she scored poorly on a cognitive screen was of
concern for the occupational therapist. This suggests that the MoCA is applicable to
occupational therapy practice as it is a means to do more in depth screening of cognition.
Additionally, one clinician reported one client “did okay on the verbal questions, but did
not perform as well on motor tasks” which was good to see both on one screen for
efficiency. Clinicians also reported that some clients did poorly on the MoCA “but
performed well on the MMS perhaps indicating the MMS is more functional.” The
clients who had difficulty with testing “often made up excuses, stating it was not their
own routine” possible indicating challenges with abstract problem solving. “Higher level
clients were tested and they found parts of the screen very challenging, such as the pill
box in the MMS” and then realized how their stroke affected their thinking skills. The
screens were a good way to start a dialogue with clients about their medication
management capacity.
Clinicians were asked to share their impression of each screen’s ability to detect
medication management skills. Clinicians stated: “All screens provided good info, some
better than others;” the MMS “did well for assessing memory, used a variety of tests and
skills, and generally indicated the client’s ability” with medication management. “You
could detect if the problem was visual, manipulation or memory” from using the MMS.
The S5 “would be hard to get enough information if you were doing it alone, as it is too
basic and vague” even though it uses a nice variety of pill and liquid bottles and a variety
of pill sizes. As the MoCA assess only memory and not performance of medication
management, “it would not be a good stand alone test.”
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In regards to treatment planning and discharge recommendations, clinicians
reported: “results will help with discharge recommendations especially related to safety,”
and “enable patient and family education regarding this task at home.” Clinicians felt that
while collecting data about one week prior to discharge was helpful, had it been done
earlier in the rehabilitation process “more nurse and doctor communication could have
happened” facilitating more in depth teaching from multiple disciplines or modification
or reduction of medications.
Theme C: Clinician’s Preference
Clinicians were asked to consider each screen, their usefulness and applicability
to practice, in order to state their preference of a screen they are most likely to adopt into
their practice. Clinicians stated they feel they could make use of all three screens in future
practice. However, “generally the MMS will be used most often” as clinicians stated in
theme A the MMS is relevant, practical, realistic, contains a variety of questions and test
items, easy to follow instructions, and it is standardized with norm values. As the
occupational therapy clinicians did not typically use the MoCA at this setting, now being
trained in its use and scoring, clinicians stated: “the MoCA will help broaden the tools we
use and enable better collaboration with SLP [speech], and its use can help increase
justification for rehab stay, and/or adding SLP services, and better communication at
team meetings for discharge planning.” Future plans for focus on medication
management with the stroke population at this hospital will entail “following through on
consistent testing, recommendations and teaching and patient education,” and these tools
can help with that.
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Clinicians reported that in general, the clients’ responses to testing were positive,
they understood the purpose and learned about themselves through the process. Clients
generally reported most difficulty with the MMS in regards to the pill box organization
task, an instrumental activity of daily living.
Clinicians also found areas of the screens that could be improved to enhance
clinical practice. Specifically, “testing was not as complicated as real life” and it “would
be helpful if a test could be tailored to the client’s actual medications or routines.” Also,
the “pill box scoring on the MMS needs clearer directions for scoring” for the clinician.
Table 8. Selected Quotes from the Focus Group
________________________________________________________________________
Regarding the MMS screen:
“relevant and practical to every life,” “good variety of questions and test items”
Regarding the S5 screen:
“It’s a good tool for clients who may be resistive to testing or easily frustrated”
Regarding the MoCA:
“does not relate to function”
Overall Comments:
“results will help with discharge recommendations especially related to safety”
“generally the MMS will be used most often”
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Results Part II
The three clinicians’ consensus revealed that they felt the MMS was the more
useful screen of all screens uses when comparing advantages and disadvantages in
regards to accuracy, efficiency, practicality and clinical relevance. This directly answers
the third research question, “Which of the medication management screening tools (or
aspects of each screen) offers the most clinically relevant information to help inform
decision making for treatment and discharge planning for medication management
capacity for occupational therapy practitioners?” While the MMS was the longest to
administer, previously mentioned advantages appear to make it the most clinically useful
tool for clients post-stroke in this setting when compared to the S5 and MoCA. The MMS
offers more clinically relevant information by screening visual, cognitive and physical
performance skills by having clients read medication information and pill bottles,
manipulate pill bottles and pills, and complete memory and problem solving tasks. The
filling of the pill organizer of the MMS was the most revealing in terms of where clients
could have difficulty with managing a medication routine. However, it was also this
component that was the most challenging for clinicians to administer and score.
Clinicians also felt that they would adopt the use of the MoCA in their clinical
practice, but not as a medication management capacity screen. The MoCA provides
clinically relevant information as it can detect what areas of cognition are challenges for
the client (visuospatial/executive, naming, memory, attention, language, abstraction,
and/or orientation). The use of the MoCA can target treatment towards compensation or
remediation approaches to the deficits. Additionally, the MoCA is well understood by the
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other team members and can create a dialogue during team rounds to ensure the client is
receiving the necessary services while in rehabilitation.
The S5 was the least likely of the screens to be frequently used by these clinicians
as it lacks usefulness and clinically relevant information. The S5 was found to be too
subjective, vague and the overall score does not relate to a norm. Generally, clinicians
felt that while the S5 was the quickest and simplest screen to administer, it did not yield
data with enough depth to be useful. Clinicians did appreciate that a variety of pill sizes,
colors, and pill or liquid bottles that were included in the screen, but the score was not as
meaningful. The S5 will continue to be a possible tool that clinicians can offer a client
should the MMS be too challenging or if the client is resistive to the screening process.
This qualitative thematic analysis based on clinician feedback suggests that
overall the MMS offers the most clinically useful and relevant information for treatment
and discharge planning.
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Discussion
Best practice would indicate the use of comprehensive and psychometrically
strong tools for client assessment; clinicians often choose assessments tools based on
their usefulness and practicality to their practice (AOTA, 2008). From the literature,
clinicians were made aware of several medication management screens available on the
market for use in practice. However, clinicians were also informed of key items that
should be included in a medication management screen, such as language abilities,
reading and writing, numeric/calculation, limb praxis, visuospatial function, social use of
language, emotional function, attention, executive function, memory and observation of
performance of medication management tasks from the literature of Donovan et al.
(2008) and Robnett et al. (2007). When comparing these key items to current assessments,
the only medication management capacity screens remaining that fit these criteria were
the MMS and S5. The MMS and S5 were chosen for further study in this capstone
because of their content and format that included cognitive and physical assessments. The
screens have also shown to have adequate psychometrics that are supported in the
literature which creates sound assessment tools for use in clinical practice. The purpose
of this capstone was to compare the consistency of scores of MMS and S5 and MoCA to
determine their usefulness in occupational therapy practice.
The results from this pilot capstone study have introduced data for the usefulness
of the ManageMed Screen and the Screening for Self-Medication Safety Post Stroke for
assessing medication management capacity for clients post-stroke. While statistical
significance of scores between the MMS and S5 was not obtained, the most significant
and consistent finding was a low score on the MMS equated to a low score on the S5.
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This potentially indicates that the MMS and S5 measure similar constructs of medication
management capacity for clients post-stroke perhaps supporting the validity of the MMS
for use with the stroke population. When comparing the MMS, S5 and MoCA, the
researcher learned there is not a consistent relationship with scores for medication
management capacity screens and cognition. However, cognition is one factor in
medication management capacity that can be assessed with the MoCA which enables the
clinician to determine what area of cognition may be impacting performance with
medication management.
The second focus of the capstone utilized qualitative analysis of clinician
responses for the usefulness of the medication management screens in clinical practice.
General consensus is that occupational therapy practitioners preferred the use of MMS
due to the depth and breadth of information the screen was able to provide. This
information then aids to inform clinical practice regarding client safety with medication
management. Clinicians did state that the cost of the kit to their department was not a
deterrent to obtaining and using this kit. Overall, clinicians indicated in their responses
that the MMS offered the most useful information to inform their practice for clients
post-stroke as it assesses “reading, medication knowledge base, problem solving, shortterm and prospective memory, and calculations, and lastly a performance” (Robnett &
Moyers, 2010, p. 2) all crucial to safety and independence with medication management.
In current practice, occupational therapists are often not using standardized
assessment for assessing medication management capacity in the rehabilitation setting.
‘Homegrown’ assessments lack reliability and validity, and using assessments designed
for other professions does not measure occupational therapy outcomes (Doucet &
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Gutman, 2013). Occupational therapy practitioners need to adopt new, valid, reliable,
easily administered and client-friendly tools to strive for professional excellence and
effectiveness (Doucet, 2013). It appears the MMS is a useful screen that could be adopted
in occupational therapy with clients after they have sustained a stroke.
This capstone pilot study does give merit and cause for on-going research of this
nature. The trends and clinician comments indicate that there is a difference in client
performance and utility for each screen. A research study with a greater sample size
conducted over a longer period of time could yield data that has more statistical
significance. Further research is needed on the general topic of medication management
capacity in occupational therapy. Additionally, further research is needed on the use of
medication management screens for clients post-stroke.
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Study Limitations
A number of limitations must be considered in the interpretations of this pilot study’s
findings. First, the sample size for clients was small (N = 5), and even smaller for
clinicians (N=3). Because of the small sample size of clients, some clinicians only
conducted the screens on one client therefore the depth of information provided in the
focus group was limited. Additionally, the focus group was not audio recorded which
could have resulted in some loss of meaning or key phrases provided by clinicians.
Furthermore, the data collected on each screen was only a score; therefore content
of each test item could not be further analyzed. In regards to the S5, this screen did not
have norm values to relate the score to; thus the value of the score was left to subjective
interpretation. Results therefore cannot be generalized and strong conclusions regarding
comparisons between screens cannot be made.
Finally, authors of the S5 have indicated a newer version of the S5 is under study
and literature will be made available soon to the public. Researchers should review the
literature and research for this newer version and utilize it in future studies. Future studies
should include more client participants to enable clinicians to conduct screening on more
than one client for more in depth data.
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Appendix A: Sample of Medication Management Assessments
________________________________________________________________________
Assessment
Description
_____________________ ________________________________________________
Self-Administration of
Questionnaire, used by nurses to assess a person’s
Medication (SAM)
competence to self-administer medications
Medication Management
Ability Assessment
(MMAA)

Used with clients with schizophrenia, assessment in
completed through role-play

Assesses a highly functioning older adult’s ability for selfmedication by looking at ability to identify, access, dose
and time their personal medication routine
Medication Management
Used for assessment of compliance and management of
Instrument for Deficiencies medication routine
in the Elderly
(MedMaIDE)
Drug Regimen Unassisted
Grading Scale (DRUGS)

Medication Management
Tasks (MMT)

Developed for assessment of adaptive strategies in patients
with dementia

MedTake Test (MT)

Assesses understanding of dosage, indications, schedule,
and safety through interview of older adults

Self-Medication
Assessment Tool (SMAT)

Used by pharmacists to assess deficits in self-management
of medications by looking at function, cognition, selfreported adherence, medication recall

________________________________________________________________________
(Adapted from Kaizer et al., 2010)
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Appendix B: Inter-Rater Reliability
Test
MoCA

Answer Key

q1
q2
q3
q4
q5
q6
q7
q8
q9
q10
q11
q12
q13
q14
q15
q16
q17
q18
q19
q20
score

1
0
1
1
0
1
1
1
no
1
1
0
2
1
1
1
1
1
3
6
24/30

Test
S5
q1
q2
q3
q4
q5
q6
q7
q8
q9
q10
q11
q12
q13
q14
q15
q16
score

Answer Key
1
1
1
1
1
1
0
1
1
0
0
1
0
1
0
1
11/16

clinician
a score
23-May

clinician
b score
23-May

clinician
c score
17-May

clinician
d score
17-May

1
0
1
1
0
1
1
1
no
1
1
0
2
1
1
1
1
1
3
6
24/30

1
0
1
1
0
1
1
1
no
1
1
0
2
1
1
1
1
1
3
6
24/30

1
0
1
1
0
1
1
1
no
1
1
0
2
1
1
1
1
1
3
6
24/30

1
0
1
1
0
1
1
1
no
1
1
0
2
1
1
1
1
1
3
6
24/30

clinician
a score
4-Jun
1
1
1
1
1
1
0
1
1
0
0
1
0
1
0
1
11/16

clinician
b score
4-Jun
0
1
1
1
1
1
0
1
1
0
0
1
0
1
0
1
10/16

clinician
c score
4-Jun
1
1
1
1
1
1
0
1
1
0
0
1
0
1
0
1
11/16

clinician
d score
4-Jun
0
1
1
1
1
1
0
1
1
0
0
1
0
1
0
1
10/16

%

100%
100%
100%
100%
100%
100%
100%
100%
x
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100% overall test score

%
50%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
96.875% overall test score
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Test
MMS

Answer Key

clinician
a score
4-Jun

q5
q6
q7
q8
q9
q10
q11
q12
q13
q14
q15
q16
q17
q18
q19
q20
q21
q22
q23
q24
q25
q26
q27
grid
q29
q30
score

1
0
1
0
1
1
1
2
1
1
0
1
1
0
1
0
1
1
0
1
1
2
1
pink 2/3, green 3/3, white 2/4
1
1
28/39

1
0
1
0
1
1
1
2
1
1
0
1
1
0
1
0
1
1
0
1
1
2
1
1, 3, 3
1
1
28/39

clinician
b score
4-Jun
1
1
1
0
1
1
1
2
1
1
0
1
1
0
1
0
1
1
0
1
1
2
1
2, 2, 3
1
1
29/39

clinician
c score
4-Jun

clinician
d score
4-Jun

1
1
1
0
1
1
1
2
1
1
0
1
1
0
1
0
1
1
0
1
1
2
1
2, 3, 2
1
1
29/39

1
0
1
0
1
1
1
2
1
1
0
1
1
0
1
0
1
1
0
1
1
2
1
3, 3, 2
1
1
29/39

80

%

100%
50%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
100%
50%, 25%, 50%
100%
100%
91.964% overall test score
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MEDICATION MANAGEMENT CAPACITY POST-STROKE
Screening for Safe Self-medication Post Stroke Scale (S-5)
Instructions for Administration
Note: If patient wears glasses, make sure they are worn throughout the test.
Note: If patient has upper limb paralysis give demonstration using one hand where
appropriate.
Materials required
1- Pill bottle with childproof cap
2- Pill bottle without childproof cap
3- Pill bottle with a pharmacy label: must include the information commonly found on a label
(medication name, dosage, frequency, time of day to take medication and the name of a
person)
4- Liquid bottle with “push and turn” cover and a medicine cup
5- 1 syringe without needle
6- 8 disc-shaped white pills (e.g.: shape of a vitamin C)
7- 1 oval-shaped blue or green gel-capsule pill
8- 1 oval shaped orange pill
9- 1 small and 1 larger disc-shaped white pill
10- Three objects: pen, coin & a key

Diagram #1 - indicating placement of pills for questions #11 and #12

Diagram #2 - indicating placement of pills for question #13
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Screening for Self-Medication Safety Post Stroke Scale (S-5)
Evaluator’s name: ____________________ Date: _____________________________
Dysphagia (Y / N): _____________________ Mini-Mental State Examination Score (if available):
______
*Concerns and Recommendations (Note further testing/referrals/training needed)
Questions 1-3: Patient needs to succeed in 2/3 questions to continue screening
1. Say: What month is it? (Accept +/- 1 month from the correct month)
2. Say: What time of the day is it? (Should identify morning, afternoon or evening)
3. Say: Where are we right now? (Should identify name of hospital or ward or site)
4. Provide an open bottle with 8 identical white disc-shaped pills and say: If you have
to take2 pills in the morning and 2 at night, show me how you would group the pills.
(Repeat once if needed)
5. Provide a pill bottle label and say: Can you read to me what it says on the label?
6. Present a pen, coin, and key and say: Remember these three objects: a pen, a coin
and a key. Remove the objects and ask patient to name the objects. Please tell me what
they are. (Patient must correctly name all 3 objects.) Then say: I will ask you to
remember these objects later.
7. Provide a pill bottle with childproof cap and say: Open this bottle and take out one pill.
(If accomplished: skip to #9, If not accomplished: proceed to #8)
8. Provide a pill bottle without childproof cap and say: Open this bottle and take one pill.
Self-Injection (Assess if necessary)
9. Provide a syringe without a needle and ask patient to demonstrate how to inject their
medication. Note if patient uses 1 or 2 hands. ____________
10. Say: Can you name the three objects I showed you earlier? (Patient must correctly
name 2/3.)
Randomly place 3 pills (blue, orange, and white) in triangle with pill bottle as in diagram
#1.
11. Say: Point to the disc-shaped pill, then to the oval pill, and finally to the capsuleshaped pill. (Patient must correctly identify all 3)
12. Say: Point to the blue pill, then to the orange pill and finally to the white pill.
(Patient must correctly identify all 3)
Place 2 disc-shaped pills (large and small) with pill bottle in the middle as in diagram #2.
13. Say: Point to the large and then to the small sized pill. (Patient must correctly identify
both pills.)
14. Say: Imagine you need to take 3 pills every day for your blood pressure and you
only have one pill left. Suppose you cannot go to a pharmacy for 4 days, what do
you do? (Repeat once if needed)
15. Provide a liquid medication bottle with “push and turn” cover and say: Open the bottle
and pour 10 ml of the liquid into this cup. (Accept +/- 2 ml from 10ml)
16. Say: Do you feel confident in taking your medication on your own?

Yes

No
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Appendix G: Data Collection Sheet
1.)Participant # _____
2.)Age: ______

3.)Gender: female

5.)Stroke location: R hemisphere stroke
6.)Stroke type:
Embolic

Date: _________
male

4.)Hand dominance: right

L hemisphere stroke
Hemorrhagic

left

Unknown

7.)Number of days post-stroke: ________
8.)Number of different medications currently taking: ________
• 9.)circle if any of the participants medications fall into the following categories:
o antidepressant
beta blocker
barbiturates/benzodiazepines analgesics
10.) circle:
Does the participant have: visual neglect field cut cataracts glaucoma
Other visual impairment ____________________________
Ask the participant to rate the following:
11.) Since your stroke, please rate you level of stress on the scale below:
NO STRESS RARELY EVERY ONCE IN A WHILE SOMETIMES ALL THE
TIME
1
2
3
4
5
12.) Since your stroke, please rate your sleep behavior on the scale below:
NO PROBLEM
RARELY
EVERY ONCE
SOMETIMES
ALL THE TIME
A PROBLEM
IN A WHILE
1
2
3
4
5
13.) Screen score of MoCA (version B): ________
14.) Screen score of MMS: _________
15.) Screen score of S5: _________
16.) Total duration of data collection: _______minutes
Participant’s comments:
_______________________________________________________
Tester’s comments:
_______________________________________________________________________
*CLIENT SCREENED AND UNABLE TO COMPLETE DUE TO:
________________________________________________________________________
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Appendix H: Focus Group Questions
1. Share your impressions or feedback on the administration of each test, such as
ease of setup, clarity of instructions, items in test kits, questions asked
2. Describe the value of information obtained from the tests
3. What do you see as the advantage or disadvantages of each screen
4. Do you find the screens applicable to your clinical practice
5. Did anything surprise you about the participant’s performance on the tests
6. Did you find any discrepancies between test results and the client’s actual
performance
7. What were the participant’s general reactions to testing
8. Did information from the screens help you devised your treatment plans or
recommendations for discharge
9. Do you feel the MMS did well with detecting medication management skills in
clients post-stroke? The S5? Any recommendations for either test?
10. Do you have a preference as to which screen you’ll continue to use
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